A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

This study has been completed.
Sponsor:
Information provided by:
Syndax Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00828854
First received: January 23, 2009
Last updated: February 2, 2010
Last verified: February 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)